CAR-T therapies involve the genetic engineering of patients’ T-cells to express synthetic receptors, most commonly directed at PSMA, enabling precise targeting and killing of prostate cancer cells (Figure 9) [128]. Here, FOLH1 is linked to prostate cancer.